Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Trial Details

NCT ID
NCT06252649
Phase
PHASE3
Sponsor
Amgen
Status
RECRUITING
Cancer Type
Colon Cancer Colorectal Cancer
Interventions
  • FOLFIRI Regimen
  • Sotorasib
  • Panitumumab
  • Bevacizumab-awwb
Locations (sample)
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Fullerton, California, United States|33.87029,-117.92534
  • Long Beach, California, United States|33.76696,-118.18923
  • Los Alamitos, California, United States|33.80307,-118.07256
  • Los Angeles, California, United States|34.05223,-118.24368

Key Eligibility Criteria

  • Pathologically documented metastatic colorectal adenocarcinoma with KRAS p.G12C mutation by a locally validated assay.
  • Central laboratory detection of KRAS p.G12C mutation.
  • Measurable metastatic disease per RECIST v1.1 criteria.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colon Cancer Colorectal Cancer Trials on Trialify →